 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236» |
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 4, 2012
P1, N=101, Recruiting, Sponsor: Genentech
- |||| Avastin (bevacizumab) / Roche
Biomarker, Enrollment open, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 4, 2012
P4, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=1000, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Genasense (oblimersen) / Genta
Trial completion, Combination therapy, Metastases: Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2012
P1/2, N=16, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
New P2 trial: APPROACH: Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets (clinicaltrials.gov) - Jul 1, 2012
P2, N=218, Recruiting, Sponsor: Yonsei University
- | LY2090314 / Eli Lilly
New P1/2 trial, Metastases, Biopsy: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 28, 2012
P1/2, N=40, Recruiting, Sponsor: Eli Lilly and Company
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 28, 2012
P3, N=554, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- leucovorin calcium / Generic mfg.
Enrollment open: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jun 26, 2012
P2, N=144, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2012
P2, N=140, Recruiting, Sponsor: National Cancer Institute, Naples
- Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
Enrollment open: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (clinicaltrials.gov) - Jun 21, 2012
P2, N=77, Recruiting, Sponsor: Polish Lymphoma Research Group
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Jun 2012
- |||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- |||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Jun 18, 2012
P2/3, N=1060, Recruiting, Sponsor: North Central Cancer Treatment Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jun 16, 2012
P2, N=73, Completed, Sponsor: North Central Cancer Treatment Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jun 13, 2012
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer (clinicaltrials.gov) - Jun 5, 2012
P2, N=35, Recruiting, Sponsor: Marks, John, M.D.
- Trial withdrawal, Metastases: S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum (clinicaltrials.gov) - Jun 4, 2012
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Withdrawn
- Enrollment change, Metastases: S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum (clinicaltrials.gov) - Jun 4, 2012
P2, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Active, not recruiting --> Withdrawn N=65 --> 0
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
New P1/2 trial, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jun 3, 2012
P1/2, N=50, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
- || veliparib (ABT-888) / AbbVie
Enrollment change, Combination therapy, Metastases: Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor (clinicaltrials.gov) - May 30, 2012
P1, N=60, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=65 --> 0 N=36 --> 60
- |||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - May 23, 2012
P3, N=900, Recruiting, Sponsor: Sanofi
N=36 --> 60 Not yet recruiting --> Recruiting
- New P1 trial: Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion: MIROX: Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases (clinicaltrials.gov) - May 20, 2012
P3, N=284, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Surgery, Metastases: Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) (clinicaltrials.gov) - May 20, 2012
P3, N=700, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Completed Recruiting --> Completed
- |||| linifanib (ABT-869) / AbbVie
Trial completion, Combination therapy, Metastases: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer (clinicaltrials.gov) - May 17, 2012
P2, N=159, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- | leucovorin calcium / Generic mfg.
New P2 trial: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - May 16, 2012
P2, N=144, Recruiting, Sponsor: University of Arkansas
- | Stivarga (regorafenib) / Bayer
Trial completion, Combination therapy, Metastases: Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI (clinicaltrials.gov) - May 14, 2012
P1, N=45, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial initiation date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - May 8, 2012
P=N/A, N=18, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Initiation date: May 2012 --> Aug 2012
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia (clinicaltrials.gov) - May 7, 2012
P2/3, N=640, Recruiting, Sponsor: Children's Oncology Group
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2012
P3, N=315, Recruiting, Sponsor: Children's Oncology Group
Initiation date: May 2012 --> Aug 2012 N=244 --> 315
- New P2 trial: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - May 2, 2012
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 2, 2012
P1, N=19, Completed, Sponsor: Novartis Pharmaceuticals
N=244 --> 315 Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
New P2 trial: Investigation of efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients with colorectal cancer liver metastasis (EUDRACT) - May 1, 2012
P2, N=36, Ongoing, Sponsor: ABCSG (Austrian Breast & Colorectal Cancer Study Group)
- ||||| onartuzumab (RG3638) / Roche
New P2 trial, Combination therapy, Metastases: A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer (clinicaltrials.gov) - May 1, 2012
P2, N=123, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||||| Avastin (bevacizumab) / Roche
Biomarker, New P4 trial, Metastases: ASCENT: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 29, 2012
P4, N=150, Recruiting, Sponsor: Hoffmann-La Roche
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Apr 29, 2012
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Inlyta (axitinib) / Pfizer
Trial completion, Metastases: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen (clinicaltrials.gov) - Apr 26, 2012
P2, N=171, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Biomarker, New P3 trial, Metastases: A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer (clinicaltrials.gov) - Apr 25, 2012
P3, N=175, Recruiting, Sponsor: AHS Cancer Control Alberta
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer (clinicaltrials.gov) - Apr 25, 2012
P2, N=246, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases: Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors (clinicaltrials.gov) - Apr 24, 2012
P1, N=54, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| oxaliplatin liposomal (L-OHP) / Mebiopharm
Enrollment closed: Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma (clinicaltrials.gov) - Apr 23, 2012
P1/2, N=62, Active, not recruiting, Sponsor: Mebiopharm Co., Ltd
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P2 trial: Phase II Trial Evaluating OS With Therasphere (clinicaltrials.gov) - Apr 18, 2012
P2, N=58, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | zoledronic acid / Generic mfg.
Trial completion, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Apr 16, 2012
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Suspended --> Completed
- || leucovorin calcium / Generic mfg.
New P2/3 trial: ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (clinicaltrials.gov) - Apr 10, 2012
P2/3, N=256, Recruiting, Sponsor: Institut Jerome Lejeune
- Enrollment closed, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Apr 10, 2012
P2, N=45, Active, not recruiting, Sponsor: University of California, San Francisco
Suspended --> Completed Recruiting --> Active, not recruiting
- Enrollment open, Metastases: TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 4, 2012
P2, N=2, Recruiting, Sponsor: Martin-Luther-Universit
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Cyramza (ramucirumab) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) (clinicaltrials.gov) - Apr 4, 2012
P1, N=6, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P3 trial, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - Apr 3, 2012
P3, N=900, Recruiting, Sponsor: Sanofi
- Enrollment open: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2012
P1, N=24, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- E7820 / Eisai
Trial completion, Metastases: FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 3, 2012
P1/2, N=5, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Terminated --> Completed